CONCEPT

The technology owned by LAURAS is based on new knowledge showing that activation of a signal pathway inside the immune cells (the white blood cells, T lymphocytes) inhibits the function of the immune system. During HIV infection and also in certain types of cancer, the activity of this signal pathway is highly increased due to elevated levels of a signal compound, and the function of the patient's white blood cells is strongly reduced.

LAURAS

DEVELOPS IMMUNOSTIMULATORY DRUGS THAT STIMULATE AND IMPROVE THE FUNCTION OF THE IMMUNE SYSTEM IN PATIENTS WITH IMMUNODEFICIENCIES AND CERTAIN TYPES OF CANCER